U.S. may expand Nvidia and AMD’s 15% China chips deal to other companies
H.C. Wainwright maintained its buy rating and $115.00 price target on Arcellx Inc. (NASDAQ:ACLX), currently trading at $66, following the company’s investor event at the EHA 2025 conference on Friday. InvestingPro data shows analyst targets ranging from $93 to $134, reflecting strong upside potential despite the stock appearing overvalued at current levels. The event focused on launch plans for anito-cel, the company’s BCMA-CAR-T cell therapy for multiple myeloma, rather than presenting new clinical data.
Arcellx, with a market capitalization of $3.64 billion, and its partner Kite, a Gilead Sciences (NASDAQ:GILD) subsidiary, outlined an ambitious launch strategy targeting over 160 Authorized Treatment Centers (ATCs) within the first year of launch, expected in the second half of 2026. InvestingPro analysis reveals the company maintains a healthy liquidity position with a current ratio of 4.93 and holds more cash than debt, providing financial flexibility for this expansion. This expansion pace significantly exceeds competitor launches, which initially reached 34 and 70 centers.
The companies plan to begin onboarding activities in the third quarter of 2025 to support this extensive footprint. Their strategy aims to cover the entire fourth-line-plus patient population by 2027 with more than 24,000 doses and achieve 90% commercial insurance coverage within 90 days of launch.
Kite brings substantial infrastructure to the partnership, with access to over 9,000 healthcare professionals across ATCs and community settings, including centers not currently offering other multiple myeloma cell therapies. The company has treated more than 29,000 lymphoma patients at over 550 ATCs globally, providing an established network for anito-cel’s launch.
Anito-cel will be integrated into Kite Konnect, the company’s platform for onboarding and patient access support, further leveraging Kite’s existing infrastructure for the therapy’s commercialization.
In other recent news, Arcellx, Inc. has announced the appointment of Andrew Galligan and Kristin Myers to its Board of Directors as the company prepares for the anticipated commercial launch of its lead product candidate, anito-cel, in 2026. Galligan, who brings over thirty years of financial leadership experience, previously served as CFO at Nevro Corp (NYSE:NVRO). Myers, with two decades in the healthcare industry, is currently the COO at Blue Cross Blue Shield Association. Their appointments are intended to bolster Arcellx’s commercial strategies and operations. The company’s leadership highlighted the significant experience both Galligan and Myers contribute, particularly in financial infrastructure and healthcare sector leadership. Both new board members expressed confidence in anito-cel’s potential impact on treating multiple myeloma, a cancer of plasma cells. Arcellx’s efforts in cell therapy aim to provide safer and more effective treatments, with their progress and preparations for anito-cel’s commercial launch being contingent on regulatory approval. The company has partnered with Kite, a Gilead Company, for this endeavor. These developments reflect Arcellx’s current expectations for their development pipeline and organizational growth.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.